- Home
- ALXO vs IMAB Comparison
ALXO vs IMAB Comparison
Compare ALXO & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- IMAB
- Stock Information
- Founded
- ALXO 2015
- IMAB 2014
- Country
- ALXO United States
- IMAB United States
- Employees
- ALXO N/A
- IMAB N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- IMAB Health Care
- Exchange
- ALXO Nasdaq
- IMAB Nasdaq
- Market Cap
- ALXO 76.5M
- IMAB 73.9M
- IPO Year
- ALXO 2020
- IMAB 2020
- Fundamental
- Price
- ALXO $0.55
- IMAB $0.85
- Analyst Decision
- ALXO Strong Buy
- IMAB Strong Buy
- Analyst Count
- ALXO 6
- IMAB 2
- Target Price
- ALXO $4.14
- IMAB $5.50
- AVG Volume (30 Days)
- ALXO 529.8K
- IMAB 261.6K
- Earning Date
- ALXO 05-08-2025
- IMAB 04-03-2025
- Dividend Yield
- ALXO N/A
- IMAB N/A
- EPS Growth
- ALXO N/A
- IMAB N/A
- EPS
- ALXO N/A
- IMAB N/A
- Revenue
- ALXO N/A
- IMAB N/A
- Revenue This Year
- ALXO N/A
- IMAB N/A
- Revenue Next Year
- ALXO N/A
- IMAB N/A
- P/E Ratio
- ALXO N/A
- IMAB N/A
- Revenue Growth
- ALXO N/A
- IMAB N/A
- 52 Week Low
- ALXO $0.46
- IMAB $0.60
- 52 Week High
- ALXO $17.83
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- ALXO 37.26
- IMAB 53.01
- Support Level
- ALXO $0.46
- IMAB $0.63
- Resistance Level
- ALXO $0.63
- IMAB $1.01
- Average True Range (ATR)
- ALXO 0.06
- IMAB 0.10
- MACD
- ALXO 0.02
- IMAB 0.02
- Stochastic Oscillator
- ALXO 42.86
- IMAB 60.39
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).